Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This phase I trial tests the side effects and best dose of abemaciclib and niraparib in
treating patients with breast cancer that is positive for estrogen or progesterone receptors
(hormone receptor positive [HR+]) and HER2 negative. Abemaciclib may stop the growth of tumor
cells by blocking certain proteins called cyclin-dependent kinases, which are needed for cell
growth. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as
niraparib, can keep PARP from working so tumor cells can't repair themselves and grow. Giving
abemaciclib and niraparib together before surgery may make the tumor smaller.
Phase:
Phase 1
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Eli Lilly and Company GlaxoSmithKline National Cancer Institute (NCI) Oregon Health and Science University